In particular pembrolizumab was granted in first line setting only in tumors that express a strong PD-L1 tumor proportion score (TPS≥50%) while in further lines of therapy a positivity of PD-L1 (≥1%) is sufficient to indicate its employment [14]. Here, CD274 is linked to neoplasm.